Sage Therapeutic
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $21.53
- Today's High:
- $23.58
- Open Price:
- $21.57
- 52W Low:
- $16.515
- 52W High:
- $59.99
- Prev. Close:
- $21.65
- Volume:
- 1707404
Company Statistics
- Market Cap.:
- $1.30 billion
- Book Value:
- 16.462
- Revenue TTM:
- $10.37 million
- Operating Margin TTM:
- -5990.25%
- Gross Profit TTM:
- $-319290000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -28.94%
- Return on Equity TTM:
- -47.55%
Company Profile
Sage Therapeutic had its IPO on 2014-07-18 under the ticker symbol SAGE.
The company operates in the Healthcare sector and Biotechnology industry. Sage Therapeutic has a staff strength of 689 employees.
Stock update
Shares of Sage Therapeutic opened at $21.57 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $21.53 - $23.58, and closed at $23.44.
This is a +8.27% increase from the previous day's closing price.
A total volume of 1,707,404 shares were traded at the close of the day’s session.
In the last one week, shares of Sage Therapeutic have increased by +15.52%.
Sage Therapeutic's Key Ratios
Sage Therapeutic has a market cap of $1.30 billion, indicating a price to book ratio of 1.7816 and a price to sales ratio of 366.0938.
In the last 12-months Sage Therapeutic’s revenue was $10.37 million with a gross profit of $-319290000 and an EBITDA of $-620086976. The EBITDA ratio measures Sage Therapeutic's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sage Therapeutic’s operating margin was -5990.25% while its return on assets stood at -28.94% with a return of equity of -47.55%.
In Q2, Sage Therapeutic’s quarterly earnings growth was a positive 0% while revenue growth was a positive 64.8%.
Sage Therapeutic’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.74
Its diluted EPS in the last 12-months stands at $-10.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.74. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sage Therapeutic’s profitability.
Sage Therapeutic stock is trading at a EV to sales ratio of 166.9508 and a EV to EBITDA ratio of -2.0854. Its price to sales ratio in the trailing 12-months stood at 366.0938.
Sage Therapeutic stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.08 billion
- Total Liabilities
- $96.81 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $112000
- Dividend Payout Ratio
- 0%
Sage Therapeutic ended 2024 with $1.08 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.08 billion while shareholder equity stood at $984.38 million.
Sage Therapeutic ended 2024 with $0 in deferred long-term liabilities, $96.81 million in other current liabilities, 6000.00 in common stock, $-2335323000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $121.42 million and cash and short-term investments were $1.00 billion. The company’s total short-term debt was $7,725,000 while long-term debt stood at $0.
Sage Therapeutic’s total current assets stands at $1.00 billion while long-term investments were $0 and short-term investments were $881.20 million. Its net receivables were $15.09 million compared to accounts payable of $9.28 million and inventory worth $-61411000.00.
In 2024, Sage Therapeutic's operating cash flow was $0 while its capital expenditure stood at $112000.
Comparatively, Sage Therapeutic paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $23.44
- 52-Week High
- $59.99
- 52-Week Low
- $16.515
- Analyst Target Price
- $25.81
Sage Therapeutic stock is currently trading at $23.44 per share. It touched a 52-week high of $59.99 and a 52-week low of $59.99. Analysts tracking the stock have a 12-month average target price of $25.81.
Its 50-day moving average was $31.03 and 200-day moving average was $41.68 The short ratio stood at 3.33 indicating a short percent outstanding of 0%.
Around 1254.6% of the company’s stock are held by insiders while 9217.9% are held by institutions.
Frequently Asked Questions About Sage Therapeutic
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.